Diverse combination therapies are being investigated to overcome the limitations of immune checkpoint inhibitors. However, determining the optimal combination therapy remains a challenge. Herein, we d
Cancer somatic mutations have been identified as a source of antigens that can be targeted by cancer immunotherapy. In this work, expanding on previous studies, we analyze the HLA-presentation propert
Gold(I) complexes with a 1,3-diethylbenzimidazol-2-ylidene N-heterocyclic carbene (NHC) ligand of the type NHC-Au-L (L = -Cl, -NHC, or -PPh3) were comparatively evaluated as thioredoxin reductase (Tr